Search Result

Isoforms Recommended:	NOD1

Results for "

NOD1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	NOD-like Receptor (NLR) (24) Apoptosis (1) Caspase (1) ERK (2) IAP (1) Interleukin Related (5) MAP3K (2) MEK (2) NF-κB (4) p38 MAPK (2) Reference Standards (1) RIP kinase (5) SARS-CoV (2) Small Interfering RNA (siRNA) (3)
By Research Areas:	Cancer (2) Infection (2) Inflammation/Immunology (16) Metabolic Disease (3)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Peptides

Oligonucleotides

Targets Recommended: NOD-like Receptor (NLR)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-18639

Nodinitib-1 Maximum Cited Publications 12 Publications Verification ML130; CID-1088438	NOD-like Receptor (NLR)	Inflammation/Immunology
Nodinitib-1 (ML130;CID-1088438) is a *NOD1* inhibitor with an IC₅₀ of 0.56 μM.

HY-W746708

FK-565	NOD-like Receptor (NLR)	Inflammation/Immunology
FK-565 is a nucleotide oligomerization domain-1 (NOD1) ligand. FK-565 induces murine model with arteritis ^[1].

HY-100691

NOD-IN-1 5+ Cited Publications	NOD-like Receptor (NLR)	Inflammation/Immunology
NOD-IN-1 is a potent mixed inhibitor of nucleotide-binding oligomerization domain (NOD)-like receptors, *NOD1* and *NOD2, with IC₅₀* of 5.74 μM and 6.45 μM, respectively.

HY-P5523A

iE-DAP dihydrochloride	NOD-like Receptor (NLR) NF-κB Interleukin Related	Metabolic Disease
iE-DAP dihydrochloride is a *Nod1* agonist. iE-DAP dihydrochloride activates *NOD1, which in turn activates the NF-κB* signaling pathway and MLCK signaling pathway, inducing cellular inflammatory responses and tight junction disruption. iE-DAP dihydrochloride downregulates the expression of *ZO-1* and Occludin genes. iE-DAP dihydrochloride increases the secretion of IL-6, GRO-α, *MCP-1, IL-8* and *MIP-1β* in term human trophoblast cell cultures. iE-DAP dihydrochloride triggers preterm birth in pregnant mice, reduces fetal body weight, and induces fetal inflammation. iE-DAP dihydrochloride can be used in studies related to mastitis and preterm birth ^[1] .

HY-RS09404

Nod1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) NOD-like Receptor (NLR)	Others
Nod1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Nod1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Nod1 Mouse Pre-designed siRNA Set A Nod1 Mouse Pre-designed siRNA Set A

HY-P5544

M-TriDAP N-Acetylmuramyl-L-Ala-γ-D-Glu-meso-diaminopimelic acid	NOD-like Receptor (NLR)	Others
M-TriDAP (N-Acetylmuramyl-L-Ala-γ-D-Glu-meso-diaminopimelic acid) is a *NOD1/2* agoist and biological active peptide ^[1].

HY-146034

NOD1/2 antagonist-1	NOD-like Receptor (NLR)	Inflammation/Immunology Cancer
NOD1/2 antagonist-1 (compound 36b) is a potent *NOD1/2* (nucleotide-binding oligomerization domain-like receptor 1/2) dual antagonist, with IC₅₀ values of 1.13 (NOD1) and 0.77 μM (NOD2), respectively. NOD1/2 antagonist-1 has a acceptable T_1/2 (67.6 min). NOD1/2 antagonist-1 (compound 36b) can improve the antitumor efficacy of Paclitaxel (PTX) ^[1].

HY-P5522A

TriDAP dihydrochloride 1 Publications Verification L-Ala-γ-D-Glu-meso-diaminopimelic acid dihydrochloride	NOD-like Receptor (NLR) NF-κB MAP3K MEK ERK p38 MAPK Interleukin Related SARS-CoV	Infection Inflammation/Immunology
TriDAP dihydrochloride (L-Ala-γ-D-Glu-meso-diaminopimelic acid dihydrochloride) is a *NOD1* agonist with a K_d value of 34.5 μM. TriDAP dihydrochloride enhances the binding of *NOD1-RICK*, promotes RICK phosphorylation, and activates the NF-κB, *TAK1, MEK/ERK, p38* and interferon response pathways. TriDAP dihydrochloride downregulates Runx2 via increasing ubiquitination and reduces trabecular bone parameters. TriDAP dihydrochloride decreases IκBα levels and increases p65 levels. TriDAP dihydrochloride induces the secretion of proinflammatory mediators IL-8 and prostaglandins, triggers tissue inflammation and innate immune activation, and inhibits SARS-CoV-2 replication in lung epithelial cells. TriDAP dihydrochloride increases the RANKL/OPG ratio in mice, reduces bone mass and enhances osteoclast activity, and inhibits new bone formation by decreasing the mineralization deposition rate in mice. TriDAP dihydrochloride can be used in research related to pulpitis, chronic ulcerative colitis, Crohn's disease and SARS-CoV-2 infection ^[1] .

HY-170447

NOD1 antagonist-2	NOD-like Receptor (NLR)	Inflammation/Immunology
NOD1 antagonist-2 (compound 66) is an orally active selective antagonist of both human and mouse *NOD1. NOD1* antagonist-2 (compound 66) antagonizes NOD1-induced NF-κB and MAPK pathways ^[1].

HY-P5523

iE-DAP	NOD-like Receptor (NLR) NF-κB Interleukin Related	Metabolic Disease
iE-DAP is a *Nod1* agonist. iE-DAP activates *NOD1, which in turn activates the NF-κB signaling pathway and MLCK signaling pathway, inducing cellular inflammatory responses and tight junction disruption. iE-DAP downregulates the expression of ZO-1* and Occludin genes. iE-DAP increases the secretion of IL-6, GRO-α, *MCP-1, IL-8* and *MIP-1β* in term human trophoblast cell cultures. iE-DAP triggers preterm birth in pregnant mice, reduces fetal body weight, and induces fetal inflammation. iE-DAP is applicable to research related to mastitis and preterm birth ^[1] .

HY-P5524A

C12-iE-DAP hydrochloride Lauroyl-γ-D-glutamyl-meso-diaminopimelic acid hydrochloride; γ-D-glutamyl-meso-diaminopimelic acid hydrochloride	NOD-like Receptor (NLR)	Others
C12-iE-DAP hydrochloride is the hydrochloride salt form of C12-iE-DAP (HY-P5524). C12-iE-DAP hydrochloride is a biologically active peptide that has agonistic effects on *NOD1* ^[1].

HY-163274

NOD1 antagonist-1	NOD-like Receptor (NLR)	Inflammation/Immunology
NOD1 antagonist-1 (compound 37) exhibits an antagonistic activity towards *NOD1* and a weak NOD1/NOD2 selectivity, with IC₅₀s of 9.18 μM and 20.8 μM, respectively ^[1].

HY-RS09405

Nod1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Nod1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Nod1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Nod1 Rat Pre-designed siRNA Set A Nod1 Rat Pre-designed siRNA Set A

HY-RS09403

NOD1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) NOD-like Receptor (NLR)	Others
NOD1 Human Pre-designed siRNA Set A contains three designed siRNAs for NOD1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NOD1 Human Pre-designed siRNA Set A NOD1 Human Pre-designed siRNA Set A

HY-168024

NOD1/2-IN-1	RIP kinase NOD-like Receptor (NLR)	Inflammation/Immunology
NOD1/2-IN-1 (Compound 18) is a potent RIPK2 inhibitor with an IC₅₀ value of 1.4 nM, as determined by the ADP-Glo assay. NOD1/2-IN-1 blocks the production of pro-inflammatory cytokines by inhibiting the *NOD1/NOD2* pathways, with IC₅₀ values of 18 nM and 170 nM for NOD1 and NOD2, respectively, thereby reducing inflammatory responses. NOD1/2-IN-1 can be used in studies related to colitis ^[1].

HY-P5522

TriDAP L-Ala-γ-D-Glu-meso-diaminopimelic acid	NOD-like Receptor (NLR) NF-κB MAP3K MEK ERK p38 MAPK Interleukin Related SARS-CoV	Infection Inflammation/Immunology
TriDAP (L-Ala-γ-D-Glu-meso-diaminopimelic acid) is a *NOD1* agonist with a K_d value of 34.5 μM. TriDAP enhances the binding of *NOD1-RICK*, promotes RICK phosphorylation, and activates the NF-κB, *TAK1, MEK/ERK, p38* and interferon response pathways. TriDAP downregulates Runx2 via increasing ubiquitination and reduces trabecular bone parameters. TriDAP decreases IκBα levels and increases p65 levels. TriDAP induces the secretion of proinflammatory mediators IL-8 and prostaglandins, triggers tissue inflammation and innate immune activation, and inhibits SARS-CoV-2 replication in lung epithelial cells. TriDAP increases the RANKL/OPG ratio in mice, reduces bone mass and enhances osteoclast activity, and inhibits new bone formation by decreasing the mineralization deposition rate in mice. TriDAP can be used in research related to pulpitis, chronic ulcerative colitis, Crohn's disease and SARS-CoV-2 infection ^[1] .

HY-P5524

C12-iE-DAP Lauroyl-γ-D-glutamyl-meso-diaminopimelic acid; γ-D-glutamyl-meso-diaminopimelic acid	NOD-like Receptor (NLR)	Others
C12-iE-DAP (Lauroyl-γ-D-glutamyl-meso-diaminopimelic acid) is a biological active peptide. (a lauroyl (C12) group to the glutamic residue of iE-DAP , NOD1 agonist)

HY-123924

CSLP37	RIP kinase	Inflammation/Immunology
CSLP37 is a selective RIPK2 inhibitor with an IC₅₀ of 16.3 nM. CSLP37 shows no inhibitory activity against RIPK1 and RIPK3. CSLP37 displays potent suppression of cellular NOD1 and NOD2 responses ^[1].

HY-168023

NOD1-IN-1	NOD-like Receptor (NLR)	Inflammation/Immunology
NOD1/-IN-1 (Compound 2) is a potent RIPK2 inhibitor with an IC₅₀ value of 0.65 nM determined by ADP-Glo assays. NOD1/-IN-1 selectively inhibits the *NOD1* pathway (with an IC₅₀ of 33 nM for NOD1), blocking the production of pro-inflammatory cytokines and thereby reducing inflammation. NOD1/-IN-1 is applicable for research in the field of colitis ^[1].

HY-159965

NOD1-RIPK2-IN-1	NOD-like Receptor (NLR) RIP kinase Interleukin Related	Inflammation/Immunology
NOD1-RIPK2-IN-1 (Compound 37) is a *NOD1-RIPK2* signaling pathway inhibitor with IC₅₀ values of 42 nM and 1.52 nM for *NOD1* and RIPK2, respectively. NOD1-RIPK2-IN-1 reduces the secretion of the pro-inflammatory cytokine IL-8 and can be used in the research of inflammation and immune-related diseases ^[1].

HY-P5544A

M-TriDAP TFA N-Acetylmuramyl-L-Ala-γ-D-Glu-meso-diaminopimelic acid TFA	NOD-like Receptor (NLR)	Others
M-TriDAP (N-Acetylmuramyl-L-Ala-γ-D-Glu-meso-diaminopimelic acid) TFA is a *NOD1/2* agoist and biological active peptide ^[1].

HY-101927

NOD1/2 antagonist-2	NOD-like Receptor (NLR)	Cancer
NOD1/2 antagonist-2 (Compound 26BH) is a dual *NOD1/NOD2* antagonist (IC₅₀s: 2.36 μM and 4.16 μM for NOD1 and NOD2, respectively). NOD1/2 antagonist-2 inhibits both NF-κB and MAPK inflammatory signaling, thereby sensitizing Paclitaxel (HY-B0015) to suppress Lewis lung carcinoma growth ^[1].

HY-118316

GSK223	NOD-like Receptor (NLR)	Inflammation/Immunology
GSK223 is a quinazolinone NOD1 pathway inhibitor with potential anti-inflammatory activity. GSK223 can selectively inhibit IL-8 release under iE-DAP stimulation without affecting IL-8 secretion caused by TNF receptor, TLR2 or NOD2 agonists. GSK223 does not directly inhibit RIP2 kinase activity.

HY-155151

RIPK2/3-IN-1	RIP kinase	Inflammation/Immunology
RIPK2/3-IN-1 is a potent dual RIPK2/3 kinases inhibitor with IC₅₀ values of 3 nM and 117 nM, respectively. RIPK2/3-IN-1 is against RIPK2 with IC₅₀ value 14 nM in 14-TriLAN-Gly/NOD1 THP-1 cell-based NF-κB reporter assay ^[1].

HY-178899

C14-Tri-LAN-Gly	NOD-like Receptor (NLR) Caspase Apoptosis	Metabolic Disease
C14-Tri-LAN-Gly is a highly selective and potent *NOD1* agonist. C14-Tri-LAN-Gly activates NOD1. C14-Tri-LAN-Gly inhibits the expression of cleaved-caspase3. C14-Tri-LAN-Gly upregulates A20 expression. C14-Tri-LAN-Gly protects mice from lethal hepatitis by inhibiting hepatocyte Apoptosis. C14-Tri-LAN-Gly inhibits osteoblastogenesis and promots osteoclastogenesis ^[1] .

HY-123925

CSLP43	RIP kinase IAP NOD-like Receptor (NLR)	Inflammation/Immunology
CSLP43 is a selective RIPK2 and XIAP inhibitor with an IC₅₀ of 19.9 nM against human RIPK2. CSLP43 binds to the ATP-binding pocket of RIPK2 and disrupts the interaction between RIPK2 and the BIR2 domain of XIAP or *cIAP1. CSLP43 inhibits RIPK2* ubiquitination, *NOD1*-dependent inflammatory signaling pathways, *NOD2*-dependent inflammatory signaling pathways, as well as NF-κB activation associated with NOD agonists. CSLP43 is selective for the *NOD1/NOD2* signaling pathway and does not inhibit the kinase activity of *RIPK1* or RIPK3. CSLP43 is applicable to research related to Crohn's disease, Blau syndrome, early-onset sarcoidosis and early-onset inflammatory bowel disease ^[1].

HY-100691R

NOD-IN-1 (Standard)	NOD-like Receptor (NLR) Reference Standards	Inflammation/Immunology
NOD-IN-1 (Standard) is the analytical standard of NOD-IN-1 (HY-100691). This product is intended for research and analytical applications. NOD-IN-1 is a potent mixed inhibitor of nucleotide-binding oligomerization domain (NOD)-like receptors, NOD1 and NOD2, with IC50 of 5.74 μM and 6.45 μM, respectively.

Cat. No.	Product Name	Target	Research Area